Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2004

View Archived Issues

Savient updates recent developments

Antisense morpholino-oligomers inhibit coronavirus proliferation and growth

Improved prevention of CINV found with a palonosetron combination therapy

Data on the pharmacokinetics of ramelteon presented at sleep conference

Neurogen provides update on portfolio of clinical and preclinical programs

PSMA-targeting immunotherapies presented at ASCO

Vical provides program update

Novel inotropic agent shows more potency than ouabain

Promising nonprostanoid prostacyclin receptor agonist for the treatment of chronic vascular disease

Targeting of Nurr1 gene promising for Parkinson's disease therapy

Trinam receives orphan medicinal product status in Europe

FDA sets action date for Metvix review

Copaxone PFS available in Europe

Additionional analysis of phase III U.S. trial for the Intercept Blood System

Actelion and Celltech modify Zavesca license agreement

Fast track designation for BAL-5788 in hospital-acquired pneumonia

ILX-651 in new phase II trial for hormone-refractory prostate cancer

Full enrollment in phase III Virulizin trial

New phase II trial studies talabostat for advanced metastatic melanoma

Results from confirmatory phase II study of Aquavan

Levitra enters Japanese market

Novel inhibitors of Src kinases developed at Roche

Guilford patent covers new DPPIV inhibitors and their therapeutic use

New bone or tissue-selective SARMs under study at Merck

Merck scientists develop new NO-releasing COX-2 inhibitors

Merck researchers describe new protein kinase inhibitors and their use

New TNF-alpha production inhibitors prepared and tested by Ajinomoto team

Dual PPARalpha/PPARgamma agonists presented by Roche researchers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...